Edwards(EW) GlobeNewswire News Room·2024-10-17 10:06Core Viewpoint - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims related to misleading statements about the company's TAVR platform and its market demand [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Patel v. Edwards Lifesciences Corporation, et al., No. 24-cv-02221 [2]. - Investors have until December 13, 2024, to request to lead the case [2]. Group 2: Company Overview - Edwards Lifesciences is an international company focused on heart valve repair and replacement therapies, as well as critical care monitoring solutions, categorized into four main therapy types: TAVR, TMTT, Surgical Structural Heart therapies, and Critical Care therapies [3]. Group 3: Allegations and Impact - The complaint alleges that Edwards misrepresented the demand for its TAVR platform, claiming significant unmet demand while the actual growth had stalled due to ineffective patient activation activities and prioritization of other treatments by healthcare organizations [4]. - On July 24, 2024, Edwards reduced its guidance for TAVR for fiscal 2024 and reported disappointing financial results for the second quarter, leading to a 31% decline in stock price from 59.70 per share [5][6].